Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4685 Phase 1 in Plaque Psoriasis
NCT05332704Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of ONO-4685 in plaque psoriasis (6 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Treatment emergent adverse events, Clinical laboratory tests and 4 more. Started Mar 2022; status: completed.
02
Drugs
ONO-4685
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05332704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332704.